<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table III</label>
 <caption>
  <p>MSNs as Drug Delivery Platforms for Infectious Diseases Treatment Including Bacterial, Parasitic, Fungal and Viral Infections Besides Drugs Type, MSNs-Based Carriers, Microorganisms and Drugs Absorption and Release Mechanisms</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug</th>
    <th>Carrier</th>
    <th>Assay</th>
    <th>Microorganism</th>
    <th>Adsorption mechanism</th>
    <th>Release mechanism</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Rifampicin (RIF)</td>
    <td>MSNs with 40 and 100 nm</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>Staphylococcus aureus</italic>
    </td>
    <td>Passive diffusion method</td>
    <td>Diffusion</td>
    <td>(
     <xref ref-type="bibr" rid="CR110">110</xref>)
    </td>
   </tr>
   <tr>
    <td>Levofloxacin (LEVO)</td>
    <td>MSNs decorated with lectin concanavalin A (ConA) (MSN
     <sub>ConA</sub>)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>Escherichia coli</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion</td>
    <td>(
     <xref ref-type="bibr" rid="CR111">111</xref>)
    </td>
   </tr>
   <tr>
    <td>Norfloxacin (NFX)</td>
    <td>MSNs-MCM-41, modified (vinyl groups) MSNs-MCM-41 and MSNs-MCM-48</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>E. coli</italic>
    </td>
    <td>Impregnation method</td>
    <td>Dissociation/diffusion</td>
    <td>(
     <xref ref-type="bibr" rid="CR112">112</xref>)
    </td>
   </tr>
   <tr>
    <td>Gentamicin (GEN)</td>
    <td>MSNs modified with a lipid bilayer surface shell and a bacterial-targeting peptide Ubiquicidin (UBI
     <sub>29-41</sub>) (MSNs-LU)
    </td>
    <td>
     <italic>In vitro</italic> and i
     <italic>n vivo</italic> (
     <italic>S. aureus</italic>-infected mice)
    </td>
    <td>
     <italic>S. aureus</italic>
    </td>
    <td>Impregnation method</td>
    <td>Bacteria-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR113">113</xref>)
    </td>
   </tr>
   <tr>
    <td>Vancomycin (VAN)</td>
    <td>MSNs dispersed onto gelatin matrix</td>
    <td>
     <italic>In vitro</italic> and i
     <italic>n vivo</italic> (induced bone infection)
    </td>
    <td>
     <italic>S. aureus</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR114">114</xref>)
    </td>
   </tr>
   <tr>
    <td>Lysozyme (LYZ)</td>
    <td>Hollow MSNs (HMSNs) with large and small cone shaped pores (HMSN-LP and HMSN-SP, respectively)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>E. coli</italic>
    </td>
    <td>Ultrasonication method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR115">115</xref>)
    </td>
   </tr>
   <tr>
    <td>Doxycycline (DOXY)</td>
    <td>MCM-41 modified with phenyl, mercaptopropyl, propylsulfonic and magnesium (MCM-C
     <sub>6</sub>H
     <sub>5</sub>, MCM-SH, MCM-SO
     <sub>3</sub>H and MCM-Mg, respectively)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>Klebsiella pneumoniae</italic>
    </td>
    <td>Impregnation method</td>
    <td>Dissociation/diffusion</td>
    <td>(
     <xref ref-type="bibr" rid="CR116">116</xref>)
    </td>
   </tr>
   <tr>
    <td>Ciprofloxacin (CIP)</td>
    <td>MSNs-SBA-16/hydroxyapatite (HA) modified with 3-aminopropyltriethoxysilane (APTES), anchored with diethylenetriaminepentaacetic acid (DTPA) for chelating technetium-99m (
     <sup>99</sup>mTc-DTPA-SBA-16-APTES)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <p>
      <italic>S. aureus</italic>, 
      <italic>P. aeruginosa</italic>,
     </p>
     <p>
      <italic>E. coli</italic> and 
      <italic>Bacillus cereus</italic>
     </p>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR117">117</xref>)
    </td>
   </tr>
   <tr>
    <td>Clofazimine (CFZ)</td>
    <td>MSNs loaded with CFZ + acetophenone (AP)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>Mycobacterium tuberculosis</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/AP-assisted release</td>
    <td>(
     <xref ref-type="bibr" rid="CR118">118</xref>)
    </td>
   </tr>
   <tr>
    <td>Levofloxacin (LEVO)</td>
    <td>MSN modified with [3-(2-aminoethylamino) propyl]trimethoxysilane (DAMO) (MSNs-DAMO)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>E. coli</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR119">119</xref>)
    </td>
   </tr>
   <tr>
    <td>Silver and bismuth nanoparticles (Ag and Bi, respectively)</td>
    <td>Ag-Bi@MSNs</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>methicillin-resistant 
     <italic>S. Aureus</italic> (MRSA)
    </td>
    <td>
     <italic>In situ</italic> growth of Ag and Bi nanoparticles
    </td>
    <td>Near-infrared (NIR)-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR120">120</xref>)
    </td>
   </tr>
   <tr>
    <td>DNase I(Deoxyribose nuclease I)</td>
    <td>MSN-Ag</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>E. coli</italic> and 
     <italic>Streptococcus mutans</italic> biofilms
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR121">121</xref>)
    </td>
   </tr>
   <tr>
    <td>Vancomycin (VAN)</td>
    <td>sufonated-hyaluronic acid (S-HA) terminated magnetic MSNs modified with 
     <italic>S. aureus</italic> antibody (Ab) (Ab@S-HA@MMSNs)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>S. aureus</italic>
    </td>
    <td>Impregnation method</td>
    <td>Hyaluronidase (Hyal)-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR122">122</xref>)
    </td>
   </tr>
   <tr>
    <td>Silver nanoparticles (Ag)</td>
    <td>poly-L-glutamic acid (PG) and polyallylamine hydrochloride (PAH) assembled by the layer-by-layer (LBL) technique onto MSN-Ag (LBL@MSN-Ag)</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>
     <italic>S. aureus</italic>-associated osteomyelitis infections
    </td>
    <td>
     <italic>In situ</italic> growth of Ag nanoparticles
    </td>
    <td>V8 enzyme-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR123">123</xref>)
    </td>
   </tr>
   <tr>
    <td>Levofloxacin (LEVO)</td>
    <td>mixed-charge pseudo-zwitterionic MSNs (ZMSN) and PEGylated (PEG)-MSN</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>E. coli</italic> and 
     <italic>S. aureus</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR124">124</xref>)
    </td>
   </tr>
   <tr>
    <td>Moxifloxacin (MXF)</td>
    <td>disulfide snap-top redox-operated MSNs (MSN-SS)</td>
    <td>
     <italic>In vivo</italic>
    </td>
    <td>
     <italic>Francisella tularensis</italic>
    </td>
    <td>Impregnation method</td>
    <td>Redox-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR125">125</xref>)
    </td>
   </tr>
   <tr>
    <td>Polymyxin B</td>
    <td>MSNs, aminated MSNs (N-MSNs) and carboxyl modified MSNs (C-MSNs)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>P. aeruginosa</italic>, 
     <italic>E. coli</italic> and 
     <italic>Acinetobacter baumannii</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR126">126</xref>)
    </td>
   </tr>
   <tr>
    <td>Levofloxacin (LEVO)</td>
    <td>MSNs-like SBA15, SBA15@NH
     <sub>2</sub> and SBA15@NH
     <sub>2</sub>/PLA(polylactic acid)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>S. aureus, E. coli, C. albicans and Aspergillus niger</italic>
    </td>
    <td>Impregnation method</td>
    <td>Acid pH-controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR127">127</xref>)
    </td>
   </tr>
   <tr>
    <td>Biocide Parmetol S15</td>
    <td>MSNs-like MCM-48 modified with quaternary ammonium salts (QASs)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>S. aureus</italic> and 
     <italic>E. coli</italic>
    </td>
    <td>Impregnation method</td>
    <td>Diffusion/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR128">128</xref>)
    </td>
   </tr>
   <tr>
    <td>Ethionamide (ETH)</td>
    <td>carboxylic acid functionalized thermally hydrocarbonized porous silicon nanoparticles (UnTHCPSi NPs)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>multidrug-resistant 
     <italic>M. tuberculosis</italic> (MRD-TB)
    </td>
    <td>Covalent conjugation of ETH</td>
    <td>---</td>
    <td>(
     <xref ref-type="bibr" rid="CR129">129</xref>)
    </td>
   </tr>
   <tr>
    <td>Moxifloxacin (MXF)</td>
    <td>disulfide snap-top redox-operated MSNs modified with β-cyclodextrin (β-CD) (MSN-SS- β-CD)</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>
     <italic>Francisella tularensis</italic>
    </td>
    <td>Impregnation method</td>
    <td>Redox-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR130">130</xref>)
    </td>
   </tr>
   <tr>
    <td>Isoniazid (INH)</td>
    <td>Hollow oblate MSNs (HOMSNs), trehalose-conjugated HOMSNs (HOMSNs-Tre) and mannose-conjugated HOMSNs (HOMSNs-Man)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>M. smegmatis</italic> (INH-resistant), 
     <italic>Staphylococcus epidermidis</italic> and 
     <italic>E. coli</italic>
    </td>
    <td>Impregnation method</td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR131">131</xref>)
    </td>
   </tr>
   <tr>
    <td>Isoniazid (INH)</td>
    <td>MSNs-CHO (aldehyde modified)-INH and MSNs-CHO-INH- poly(ethylene imine)-poly(ethylene glycol) (PEI-PEG)</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>
     <italic>M. tuberculosis</italic>
    </td>
    <td>Impregnation method</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR132">132</xref>)
    </td>
   </tr>
   <tr>
    <td>Isoniazid (INH) and rifampin (RIF)</td>
    <td>MSNs, PEI-MSNs and MSNs-MBI (1-methyl-1H-benzimidazole)-
     <italic>β</italic>CD (beta-cyclodextrin)
    </td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>
     <italic>M. tuberculosis</italic>
    </td>
    <td>Impregnation method</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR133">133</xref>)
    </td>
   </tr>
   <tr>
    <td>Moxifloxacin (MFX)</td>
    <td>MSNs-ANA (anilinoalkane)-
     <italic>α</italic>CD (alpha-cyclodextrin) and MSNs-MBI (1-methyl-1H-benzimidazole)-
     <italic>β</italic>CD (beta-cyclodextrin)
    </td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>
     <italic>F. tularensis</italic>
    </td>
    <td>Impregnation method</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR134">134</xref>)
    </td>
   </tr>
   <tr>
    <td>Model drugs (Fluorescein and Hoechst 33342)</td>
    <td>MSNs- Ft-LVS-LPS-FB11</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>F. tularensis</italic>
    </td>
    <td>Impregnation method</td>
    <td>Pathogen (Ft-LVS-LPS)-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR135">135</xref>)
    </td>
   </tr>
   <tr>
    <td>Antigenic Preparation of Soluble Worm (SWAP)</td>
    <td>MSNs</td>
    <td>
     <italic>In vivo</italic>
    </td>
    <td>
     <italic>S. mansoni</italic>
    </td>
    <td>Impregnation and sonication methods</td>
    <td>
     <italic>---</italic>
    </td>
    <td>(
     <xref ref-type="bibr" rid="CR136">136</xref>)
    </td>
   </tr>
   <tr>
    <td>Benznidazole (BZ)</td>
    <td>MSNs-MCM-41 functionalized with (3-glycidoxypropy) trimethoxysilane (GPTMS) and chitosan succinate (CS)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>T. cruzi</italic>
    </td>
    <td>Simple impregnation Method</td>
    <td>---</td>
    <td>(
     <xref ref-type="bibr" rid="CR137">137</xref>)
    </td>
   </tr>
   <tr>
    <td>Praziquantel (PZQ)</td>
    <td>MSNs</td>
    <td>
     <italic>In vivo</italic>
    </td>
    <td>
     <italic>S. mansoni</italic>
    </td>
    <td>Simple impregnation method</td>
    <td>Sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR138">138</xref>)
    </td>
   </tr>
   <tr>
    <td>Metronidazole (MNZ)</td>
    <td>Mesoporous silica whiskers-SBA-15 modified with tannic acid (TA)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>Trichomonas gallinae</italic>
    </td>
    <td>Simple Impregnation method</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR139">139</xref>)
    </td>
   </tr>
   <tr>
    <td>Econazole (ECO)</td>
    <td>MSNs functionalized with aminopropyl groups (MCM-41-NH
     <sub>2</sub>)
    </td>
    <td>
     <italic>In vitro</italic> and 
     <italic>In vivo</italic>
    </td>
    <td>
     <italic>C. albicans</italic>
    </td>
    <td>Simple impregnation method</td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR140">140</xref>)
    </td>
   </tr>
   <tr>
    <td>Rose Bengal (RB)</td>
    <td>Amino-modified MSNs conjugated with RB (MSNs-RB)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>C. albicans</italic>
    </td>
    <td>Simple RB conjugation</td>
    <td>Slow/controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR141">141</xref>)
    </td>
   </tr>
   <tr>
    <td>Tebuconazole (TEB)</td>
    <td>MSNs-N3 (3-[2-(2-aminoethylamino)ethylamino]propyltrimethoxysilane)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>C. albicans</italic> and 
     <italic>Saccharomyces cerevisiae</italic>
    </td>
    <td>Simple impregnation method</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR142">142</xref>)
    </td>
   </tr>
   <tr>
    <td>Zinc ions (Zn
     <sup>2+</sup>)
    </td>
    <td>ZnO@MSNs</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>In vivo</italic>
    </td>
    <td>
     <italic>Aspergillus niger</italic> (MTCC 10180 and MTCC 2196) and two strains of 
     <italic>Fusarium oxysporum</italic> (NCIM 1043 and NCIM 1072)
    </td>
    <td>
     <italic>In situ</italic> growth of Zn nanoparticles under heating
    </td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR143">143</xref>)
    </td>
   </tr>
   <tr>
    <td>Silver ions (Ag
     <sup>+</sup>)
    </td>
    <td>MSNs-AgNPs (silver nanoparticles)</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>
     <italic>C. albicans</italic>
    </td>
    <td>
     <italic>In situ</italic> AgNPs impregnation
    </td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR144">144</xref>)
    </td>
   </tr>
   <tr>
    <td>VEEV inhibitor (ML336)</td>
    <td>Lipid (1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC):Cholestrol:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000))-coated MSNs (LC-MSNs)</td>
    <td>
     <italic>In vitro</italic> (TC-83 VEEV) and 
     <italic>in vivo</italic> (TC-83 VEEV infected mice)
    </td>
    <td>Venezuelan equine encephalitis virus (VEEV)</td>
    <td>Impregnation/sonication methods</td>
    <td>pH-responsive controlled release</td>
    <td>(
     <xref ref-type="bibr" rid="CR145">145</xref>)
    </td>
   </tr>
   <tr>
    <td>---</td>
    <td>GAGs (glycosaminoglycans, sodium benzene sulfonate) mimetic-functionalized MSNs (MSNs-SO
     <sub>3</sub>)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>Herpes simplex type 1 and type 2 viruses (HSV1 and HSV2, respectively)</td>
    <td>---</td>
    <td>---</td>
    <td>(
     <xref ref-type="bibr" rid="CR146">146</xref>)
    </td>
   </tr>
   <tr>
    <td>Acyclovir (ACV)</td>
    <td>benzene sulfonate-modified MSNs, propyl thiol-modified MSNs, propyl sulfonate-modified MSNs, zwitterionic sulfonate-modified MSNs and phenyl-modified MSNs (MSNs-Phenyl-SO
     <sub>3</sub>, MSNs-Propyl-Thiol, MSNs-Propyl-SO
     <sub>3</sub>, MSNs-Zw-SO
     <sub>3</sub> and MSNs-Phenyl, respectively)
    </td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>Herpes simplex type 1 and type 2 viruses (HSV1 and HSV2, respectively)</td>
    <td>Sonication method</td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR147">147</xref>)
    </td>
   </tr>
   <tr>
    <td>---</td>
    <td>((APTES), (3-glycidyloxypropyl)trimethoxysilane (GPTMS) and trimethoxy-(2-phenylethyl)silane (TMPES) groups were used to modified MSNs surface and noted as MSNs-APTES, MSNs-GPTMS and MSNs-TMPES</td>
    <td>
     <italic>In vitro</italic>
    </td>
    <td>recombinant lentivirus with VSV-G and HIV-gp120 envelopes</td>
    <td>---</td>
    <td>---</td>
    <td>(
     <xref ref-type="bibr" rid="CR54">54</xref>)
    </td>
   </tr>
   <tr>
    <td>PCV2 GST-ORF2-E protein</td>
    <td>HMSNs</td>
    <td>
     <italic>In vitro</italic> and 
     <italic>in vivo</italic>
    </td>
    <td>Porcine circovirus type 2 (PCV2)</td>
    <td>Sonication method</td>
    <td>Slow/sustained release</td>
    <td>(
     <xref ref-type="bibr" rid="CR148">148</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
